Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1602307 | 0.87 | OGA (0.46) | GPR119MAPTGRM5HDAC2MEN1 | |
| SCHEMBL20304919 | 0.84 | SRD5A2 (0.55) | ADORA1GPR119MAPTGRM5HDAC2 | |
| SCHEMBL14720729 | 0.84 | SRD5A2 (0.47) | HDAC2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14720748 | 0.83 | CA12 (0.44) | MAPTNPSR1NPC1RAB9AMEN1 | |
| SCHEMBL20333548 | 0.83 | KMT2A (0.46) | MAPTGRM5NPC1RAB9AMEN1 | |
| SCHEMBL20304926 | 0.83 | KMT2A (0.46) | MAPTGRM5NPC1RAB9AMEN1 | |
| SCHEMBL20304927 | 0.83 | KMT2A (0.46) | MAPTGRM5NPC1RAB9AMEN1 | |
| SCHEMBL14723520 | 0.81 | ATM (0.50) | ATMADORA1GPR119MAPTNPSR1 | |
| SCHEMBL5497099 | 0.80 | MEN1 (0.55) | NPSR1GRM5MEN1KMT2AALDH1A1 | |
| SCHEMBL14720896 | 0.80 | GRM5 (0.46) | GPR119MAPTGRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3953332-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113677664-A | Tricyclic degradants of IKAROS and AIOLOS | C4医药公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-1587795-B1 | N- (1-BENZYL-2-OXO-2- (1-PIPERAZINYL) ETHYL) -1-PIPERIDINCARBOXAMID-DERIVATIVES AND RELATED COMPOUNDS USE AS CGRP-ANTAGONISTS FOR TREATING A HEADACHE | BOEHRINGER INGELHEIM INT (DE) | 2009-05-13 | — | — | EP | disclosed |
| CN-1738805-A | N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivatives and related compounds use as CGRP-antagonists for treating a headache | BOEHRINGER INGELHEIM INT (DE) | 2006-02-22 | — | — | CN | disclosed |
| EP-1587795-A1 | N- (1-BENZYL-2-OXO-2- (1-PIPERAZINYL) ETHYL) -1-PIPERIDINCARBOXAMID-DERIVATIVES AND RELATED COMPOUNDS USE AS CGRP-ANTAGONISTS FOR TREATING A HEADACHE | Boehringer Ingelheim International GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-20040192729-A1 | Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004063171-A1 | N- (1-BENZYL-2-OXO-2- (1-PIPERAZINYL) ETHYL) -1-PIPERIDINCARBOXAMID-DERIVATIVES AND RELATED COMPOUNDS USE AS CGRP-ANTAGONISTS FOR TREATING A HEADACHE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192729-A1 | Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof | NPY1R, ADCY1, SRD5A1 | ATM 3814/4885ADORA1 5/4885GPR119 236/4885 |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | ATM 1094/4885ADORA1 4322/4885GPR119 4392/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | ATM 1094/4885ADORA1 4322/4885GPR119 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.